Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen alliance 'evolution' of AstraZeneca's peer-to-peer deal model

This article was originally published in Scrip

Executive Summary

"We like these peer-to-peer collaborations, they are a good way to work," AstraZeneca's vice president of strategic partnering and business development, Shaun Grady, told Scrip. He was discussing this week's announcement that the Anglo-Swedish pharma has signed an agreement with Amgen to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio, including the Phase III-ready brodalumab (AMG827). The other four assets are in Phase I (, 3 April 2012).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts